Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors.

PubWeight™: 1.16‹?› | Rank: Top 10%

🔗 View Article (PMC 3039654)

Published in PLoS One on February 15, 2011


Esther D Quakkelaar1, Anke Redeker, Elias K Haddad, Alexandre Harari, Stella Mayo McCaughey, Thomas Duhen, Abdelali Filali-Mouhim, Jean-Philippe Goulet, Nikki M Loof, Ferry Ossendorp, Beatriz Perdiguero, Paul Heinen, Carmen E Gomez, Karen V Kibler, David M Koelle, Rafick P Sékaly, Federica Sallusto, Antonio Lanzavecchia, Giuseppe Pantaleo, Mariano Esteban, Jim Tartaglia, Bertram L Jacobs, Cornelis J M Melief

Author Affiliations

1: Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands.

Articles citing this

CD4 T follicular helper cell dynamics during SIV infection. J Clin Invest (2012) 2.55

Cross-presentation and genome-wide screening reveal candidate T cells antigens for a herpes simplex virus type 1 vaccine. J Clin Invest (2012) 1.16

Vaccinomics, adversomics, and the immune response network theory: individualized vaccinology in the 21st century. Semin Immunol (2013) 1.11

Improved NYVAC-based vaccine vectors. PLoS One (2011) 1.04

The evolution of poxvirus vaccines. Viruses (2015) 1.02

Poxvirus vectors as HIV/AIDS vaccines in humans. Hum Vaccin Immunother (2012) 1.00

Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice. J Virol (2012) 0.98

Virus inhibition activity of effector memory CD8(+) T cells determines simian immunodeficiency virus load in vaccinated monkeys after vaccine breakthrough infection. J Virol (2012) 0.97

Development of replication-competent viral vectors for HIV vaccine delivery. Curr Opin HIV AIDS (2013) 0.96

Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens. PLoS One (2012) 0.96

The canarypox virus vector ALVAC induces distinct cytokine responses compared to the vaccinia virus-based vectors MVA and NYVAC in rhesus monkeys. J Virol (2013) 0.92

Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways. PLoS One (2013) 0.92

Nonhuman primate models for HIV/AIDS vaccine development. Curr Protoc Immunol (2013) 0.88

Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C. PLoS One (2012) 0.87

Enhancing poxvirus vectors vaccine immunogenicity. Hum Vaccin Immunother (2014) 0.85

Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens. J Virol (2014) 0.83

Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates. J Virol (2015) 0.83

Interleukin-1- and type I interferon-dependent enhanced immunogenicity of an NYVAC-HIV-1 Env-Gag-Pol-Nef vaccine vector with dual deletions of type I and type II interferon-binding proteins. J Virol (2015) 0.79

Perpetuation of vaccine memory T cell responses against SIV/HIV. EMBO Mol Med (2011) 0.77

Attenuation and immunogenicity of host-range extended modified vaccinia virus Ankara recombinants. Vaccine (2013) 0.76

HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates. J Virol (2017) 0.75

Articles cited by this

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62

Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol (1994) 22.96

Antibody neutralization and escape by HIV-1. Nature (2003) 21.48

Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A (2003) 12.75

HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A (2000) 11.51

Amplified RNA synthesized from limited quantities of heterogeneous cDNA. Proc Natl Acad Sci U S A (1990) 11.10

HIV vaccine design and the neutralizing antibody problem. Nat Immunol (2004) 9.48

The influence of HLA genotype on AIDS. Annu Rev Med (2001) 7.77

Proliferating dendritic cell progenitors in human blood. J Exp Med (1994) 7.67

A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity (2008) 5.89

Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol (2006) 4.68

Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med (2009) 4.27

Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med (2008) 4.21

The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med (2008) 4.15

Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature (1999) 4.13

Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell (1995) 3.51

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med (2008) 3.42

NYVAC: a highly attenuated strain of vaccinia virus. Virology (1992) 3.38

Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol (2005) 3.23

Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys. J Immunol (1999) 3.17

Cancer immunotherapy by dendritic cells. Immunity (2008) 3.09

Major histocompatibility complex class I alleles associated with slow simian immunodeficiency virus disease progression bind epitopes recognized by dominant acute-phase cytotoxic-T-lymphocyte responses. J Virol (2003) 3.06

Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling. J Biol Chem (1995) 2.27

Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci U S A (1996) 2.10

The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN. J Virol (2000) 2.08

Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity. J Virol (1995) 2.07

Vaccinia virus host range genes. Virology (1990) 2.02

Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses. J Immunol (2002) 1.89

Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype. Proc Natl Acad Sci U S A (2007) 1.88

Association of HLA types A1-B8-DR3 and B27 with rapid and slow progression of HIV disease. QJM (1996) 1.88

HLA-B63 presents HLA-B57/B58-restricted cytotoxic T-lymphocyte epitopes and is associated with low human immunodeficiency virus load. J Virol (2005) 1.76

Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC. J Virol (2007) 1.68

The interferon system and vaccinia virus evasion mechanisms. J Interferon Cytokine Res (2009) 1.67

Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis (1998) 1.66

EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine (2008) 1.62

The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr Gene Ther (2008) 1.57

Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy. J Immunol (2002) 1.52

Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. Vaccine (2006) 1.37

Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene. J Virol (2006) 1.35

Direct priming and cross-priming contribute differentially to the induction of CD8+ CTL following exposure to vaccinia virus via different routes. J Immunol (2002) 1.28

Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases. J Leukoc Biol (1995) 1.27

EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. Vaccine (2008) 1.25

Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity. Proc Natl Acad Sci U S A (2009) 1.24

Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. Vaccine (2006) 1.18

Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates. J Virol (2008) 1.17

Diversity in the acute CD8 T cell response to vaccinia virus in humans. J Immunol (2005) 1.16

Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens. PLoS One (2010) 1.15

Comparison of human and rhesus macaque T-cell responses elicited by boosting with NYVAC encoding human immunodeficiency virus type 1 clade C immunogens. J Virol (2009) 1.11

Stable expression of the vaccinia virus K1L gene in rabbit cells complements the host range defect of a vaccinia virus mutant. J Virol (1994) 1.09

Equivalent immunogenicity of the highly attenuated poxvirus-based ALVAC-SIV and NYVAC-SIV vaccine candidates in SIVmac251-infected macaques. Virology (2002) 1.08

Detection of a protein encoded by the vaccinia virus C7L open reading frame and study of its effect on virus multiplication in different cell lines. J Gen Virol (1993) 1.04

Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS. Hum Vaccin (2009) 1.02

In vivo antigen stability affects DNA vaccine immunogenicity. J Immunol (2007) 0.96

Safety and immunogenicity of recombinants based on the genetically-engineered vaccinia strain, NYVAC. Dev Biol Stand (1994) 0.94

Role of genes that modulate host immune responses in the immunogenicity and pathogenicity of vaccinia virus. J Virol (2005) 0.92

ORFeome approach to the clonal, HLA allele-specific CD4 T-cell response to a complex pathogen in humans. J Immunol Methods (2009) 0.91

Vaccinia virus-specific CD8(+) T-cell responses target a group of epitopes without a strong immunodominance hierarchy in humans. Hum Immunol (2008) 0.86

Tissue typing of cells in culture. III. HLA antigens of established human cell lines. Attempts at typing by the mixed hemadsorption technique. Tissue Antigens (1978) 0.77

Articles by these authors

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62

Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol (2004) 17.54

Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol (2007) 13.70

Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med (2006) 13.15

Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol (2007) 12.72

Maintenance of serological memory by polyclonal activation of human memory B cells. Science (2002) 8.75

HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med (2009) 8.45

A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science (2011) 7.86

Development of a human adaptive immune system in cord blood cell-transplanted mice. Science (2004) 7.07

Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol (2005) 6.81

C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol (2009) 5.97

Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol (2004) 5.80

Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med (2009) 5.79

Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One (2010) 5.73

Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med (2007) 5.22

An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med (2004) 4.89

Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A (2008) 4.71

Medicine. The need for a global HIV vaccine enterprise. Science (2003) 4.70

Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol (2009) 4.69

Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med (2003) 4.64

Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest (2010) 4.62

Standardization of cytokine flow cytometry assays. BMC Immunol (2005) 4.55

Dendritic cell immunotherapy: mapping the way. Nat Med (2004) 4.28

Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood (2003) 4.24

Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med (2008) 4.21

Progressive differentiation and selection of the fittest in the immune response. Nat Rev Immunol (2002) 4.17

Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med (2009) 4.03

HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proc Natl Acad Sci U S A (2005) 4.02

Follicular B helper T cell activity is confined to CXCR5(hi)ICOS(hi) CD4 T cells and is independent of CD57 expression. Eur J Immunol (2006) 3.85

Pathogen-induced human TH17 cells produce IFN-γ or IL-10 and are regulated by IL-1β. Nature (2012) 3.85

Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection. Nat Med (2010) 3.81

A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood (2003) 3.77

Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity (2013) 3.72

Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med (2007) 3.66

T cell fitness determined by signal strength. Nat Immunol (2003) 3.65

Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med (2007) 3.63

Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management? Neurology (2012) 3.63

The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for presentation to T cells. J Immunol (2002) 3.48

The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe (2010) 3.48

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med (2008) 3.42

Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet (2002) 3.32

From vaccines to memory and back. Immunity (2010) 3.30

Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia. J Exp Med (2005) 3.29

Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. Blood (2003) 3.23

Understanding the generation and function of memory T cell subsets. Curr Opin Immunol (2005) 3.22

CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J Clin Invest (2008) 3.11

Memory and flexibility of cytokine gene expression as separable properties of human T(H)1 and T(H)2 lymphocytes. Nat Immunol (2002) 3.07

Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J Immunol (2005) 3.04

T cell costimulation by chemokine receptors. Nat Immunol (2005) 3.00

Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur J Immunol (2006) 2.94

Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis (2012) 2.89

Broadly neutralizing antiviral antibodies. Annu Rev Immunol (2013) 2.77

Dominant TNF-α+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease. Nat Med (2011) 2.77

Functional signatures of protective antiviral T-cell immunity in human virus infections. Immunol Rev (2006) 2.75

Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes. Proc Natl Acad Sci U S A (2005) 2.70

CD25+ cell depletion hastens the onset of severe disease in collagen-induced arthritis. Arthritis Rheum (2003) 2.68

Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis (2012) 2.68

CD4 T follicular helper cell dynamics during SIV infection. J Clin Invest (2012) 2.55

CXCR5 expressing human central memory CD4 T cells and their relevance for humoral immune responses. J Immunol (2011) 2.54

Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. Lancet (2012) 2.54

Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases. Nat Rev Immunol (2006) 2.52

Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. J Clin Oncol (2011) 2.52

L-selectin-negative CCR7- effector and memory CD8+ T cells enter reactive lymph nodes and kill dendritic cells. Nat Immunol (2007) 2.51

Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets. PLoS Med (2009) 2.47

Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J Exp Med (2012) 2.46

The inhibiting Fc receptor for IgG, FcγRIIB, is a modifier of autoimmune susceptibility. J Immunol (2011) 2.44

Chemokine receptor expression identifies Pre-T helper (Th)1, Pre-Th2, and nonpolarized cells among human CD4+ central memory T cells. J Exp Med (2004) 2.38

Immune surveillance by CD8αα+ skin-resident T cells in human herpes virus infection. Nature (2013) 2.38

Bcl6 and Maf cooperate to instruct human follicular helper CD4 T cell differentiation. J Immunol (2012) 2.34

Polymorphisms in TLR2 are associated with increased viral shedding and lesional rate in patients with genital herpes simplex virus Type 2 infection. J Infect Dis (2007) 2.33

Autoreactive T cells in healthy individuals. J Immunol (2004) 2.29

Inadequate T follicular cell help impairs B cell immunity during HIV infection. Nat Med (2013) 2.29